Cystic fibrosis and pregnancy in the modern era: A case control study

Slides:

Advertisements

Similar presentations

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

The prevalence of “risky behaviour” in adults with cystic fibrosis

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Scott D. Sagel, Marci K. Sontag, Meg M

Katarine Egressy, Michaelene Jansen, Keith C. Meyer

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy Edith T. Zemanick, J. Kirk Harris,

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Delayed publication of clinical trials in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Vitamin A and lung function in CF

Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous ΔF508 controls Jonathan McCormick, Simon A. Ogston,

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

M. Wouthuyzen-Bakker, F.A.J.A. Bodewes, H.J. Verkade

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

M. Al-Aloul, M. Jackson, G. Bell, M. Ledson, M. Walshaw

Physiologic endpoints for clinical studies for cystic fibrosis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

E. Tschiedel, H. Grasemann, F. Ratjen Journal of Cystic Fibrosis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Nasal polyposis in lung transplant recipients with cystic fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients E.B. Wilms, D.J. Touw, H.G.M. Heijerman

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention H. White, K. Pollard, C. Etherington, I. Clifton,

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

F. Vermeulen, P. Lebecque, K. De Boeck, T. Leal

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

CFTR modulators and pregnancy: Our work has only just begun

Beta-lactam allergy in adults with cystic fibrosis

Cheryl Cameron, Mark W. Lodes, William M. Gershan

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Treatment intensity and characteristics of MRSA infection in CF

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population Elaine.

Presentation transcript:

Cystic fibrosis and pregnancy in the modern era: A case control study Monica Ahluwalia, Jeffrey B. Hoag, Anas Hadeh, Marianne Ferrin, Denis Hadjiliadis Journal of Cystic Fibrosis Volume 13, Issue 1, Pages 69-73 (January 2014) DOI: 10.1016/j.jcf.2013.08.004 Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Timeline graph depicting time period when data was collected in each group (before pregnancy, end of pregnancy, after pregnancy and at last follow-up). Journal of Cystic Fibrosis 2014 13, 69-73DOI: (10.1016/j.jcf.2013.08.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Average Body Mass Index (BMI) during various time periods in pregnant and non-pregnant cystic fibrosis patients. The follow-up period represents an average of 4.5years after pregnancy. There is no significant difference in change between BMI at baseline and BMI at the end and after pregnancy (p>0.2). Journal of Cystic Fibrosis 2014 13, 69-73DOI: (10.1016/j.jcf.2013.08.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Average FEV1% predicted during various time periods in pregnant and non-pregnant cystic fibrosis patients. There is no significant difference between FEV1% at baseline and at the end and after pregnancy when comparing pregnant and non-pregnant CF patients (p>0.2). Journal of Cystic Fibrosis 2014 13, 69-73DOI: (10.1016/j.jcf.2013.08.004) Copyright © 2013 European Cystic Fibrosis Society. Terms and Conditions